Prognostic impact of concurrent EBV infection in CD30⁺ DLBCL. (A) OS of all CD30⁺EBER⁺ vs all CD30⁺EBER^– DLBCL patients. Age range, 52 to 91 for EBV⁺ group; 16 to 84 for EBV^– group. (B) OS of CD30⁺EBER⁺ vs CD30⁺EBER^– DLBCL patients in >60-year-old age group. Median age, 73 for EBV⁺ group; 70 for EBV^– group. (C) OS of CD30⁺EBV⁺ DLBCL patients in >50-year-old age group vs CD30⁺EBV^– DLBCL in >60-year-old age group. Median age, 70 for both groups.